Jacobs Levy Equity Management’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-555,826
| Closed | -$477K | – | 1085 |
|
|
2023
Q4 | $477K | Sell |
555,826
-2,778
| -0.5% | -$2.39K | ﹤0.01% | 837 |
|
|
2023
Q3 | $598K | Sell |
558,604
-20,282
| -4% | -$21.7K | ﹤0.01% | 766 |
|
|
2023
Q2 | $1.5M | Sell |
578,886
-164,353
| -22% | -$426K | 0.01% | 624 |
|
|
2023
Q1 | $3.03M | Buy |
743,239
+70,075
| +10% | +$286K | 0.02% | 491 |
|
|
2022
Q4 | $3.38M | Buy |
673,164
+604,515
| +881% | +$3.03M | 0.02% | 463 |
|
|
2022
Q3 | $898K | Buy |
+68,649
| New | +$898K | 0.01% | 730 |
|
|
2022
Q2 | – | Sell |
-351,943
| Closed | -$5.37M | – | 1114 |
|
|
2022
Q1 | $5.37M | Sell |
351,943
-76,483
| -18% | -$1.17M | 0.04% | 402 |
|
|
2021
Q4 | $7.59M | Sell |
428,426
-29,520
| -6% | -$523K | 0.05% | 353 |
|
|
2021
Q3 | $9.63M | Buy |
457,946
+205,123
| +81% | +$4.31M | 0.06% | 302 |
|
|
2021
Q2 | $4.99M | Buy |
252,823
+22,351
| +10% | +$441K | 0.03% | 430 |
|
|
2021
Q1 | $6.7M | Buy |
230,472
+12,266
| +6% | +$357K | 0.05% | 372 |
|
|
2020
Q4 | $6.61M | Sell |
218,206
-10,624
| -5% | -$322K | 0.06% | 342 |
|
|
2020
Q3 | $3.64M | Buy |
228,830
+29,434
| +15% | +$468K | 0.04% | 410 |
|
|
2020
Q2 | $3.94M | Buy |
199,396
+61,432
| +45% | +$1.21M | 0.04% | 390 |
|
|
2020
Q1 | $1.7M | Buy |
+137,964
| New | +$1.7M | 0.02% | 513 |
|